Dan F. Smelter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dan F. Smelter has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Raymond Frei
University of Texas at Austin
4 shared publications - Alvaro Moreira
Department of Pediatrics, University of Texas Health San Antonio, San Antonio, TX, USA
2 shared publications - Cody A. Black
College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
2 shared publications - Gerard Gawrys
College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
2 shared publications - Grace C. Lee
College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
2 shared publications - Jim M. Koeller
College of Pharmacy, The University of Texas at Austin, Austin, TX 78701, USA
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Treatment patterns and healthcare utilization for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the Veterans Health Administration (MCLOVA) who were prescribed their first Bruton Tyrosine Kinase inhibitor (BTKi): A national retrospective cohort study
Introduction: Mantle cell lymphoma (MCL) is a rare subtype (5%) of Non-Hodgkin Lymphoma (NHL), with 5-year survival of about 50%. Bruton Tyrosine Kinase inhibitors (BTKis) may improve health outcomes for patients with relapsed or refractory (R/R) MCL. Study objective: The objective of this study was to compare treatment patterns and healthcare utilization for patients with R/R MCL prescribed their first BTKi therapy using data from the national Veterans Health Administration (VHA). Methods: This was a retrospective cohort study of adult patients (18 + years) prescribed BTKis for MCL in all VHA medical facilities in the United States from 1/1/20 to 12/31/23. Data were statistically analyzed using chi-square, Wilcoxon Rank-Sum test, Kaplan-Meier (KM) curves, multivariable negative binomial regression, and Cox Proportional Hazards regression, and a p-value <0.05. Results: There were 494 patients included. Of those included, 177 received ibrutinib, 189 received acalabrutinib, and 128 received zanubrutinib. More patients on ibrutinib switched to other BTKis (27%) compared to patients on acalabrutinib (10%, p < 0.01) or zanubrutinib (9%, p < 0.01). Median (interquartile range [IQR]) laboratory visits at 12 months were higher for ibrutinib (5, 0–12) than acalabrutinib (1, 0–8, p < 0.01) or zanubrutinib (0, 0–6, p < 0.01). Finally, overall survival (OS) was higher for patients on zanubrutinib than those on ibrutinib (p < 0.01) or acalabrutinib (p < 0.01). Conclusions: Patients prescribed acalabrutinib and zanubrutinib experienced fewer laboratory and hematology/oncology visits at 12 months than patients who received ibrutinib. Patients who received zanubrutinib experienced a survival advantage when compared to those treated with ibrutinib.
- 28 October 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Open AccessTreatment patterns and healthcare utilization for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the Veterans Health Administration (MCLOVA) who were prescribed their first Bruton Tyrosine Kinase inhibitor (BTKi): A national retrospective cohort study
Introduction: Mantle cell lymphoma (MCL) is a rare subtype (5%) of Non-Hodgkin Lymphoma (NHL), with 5-year survival of about 50%. Bruton Tyrosine Kinase inhibitors (BTKis) may improve health outcomes for patients with relapsed or refractory (R/R) MCL. Study objective: The objective of this study was to compare treatment patterns and healthcare utilization for patients with R/R MCL prescribed their first BTKi therapy using data from the national Veterans Health Administration (VHA). Methods: This was a retrospective cohort study of adult patients (18 + years) prescribed BTKis for MCL in all VHA medical facilities in the United States from 1/1/20 to 12/31/23. Data were statistically analyzed using chi-square, Wilcoxon Rank-Sum test, Kaplan-Meier (KM) curves, multivariable negative binomial regression, and Cox Proportional Hazards regression, and a p-value <0.05. Results: There were 494 patients included. Of those included, 177 received ibrutinib, 189 received acalabrutinib, and 128 received zanubrutinib. More patients on ibrutinib switched to other BTKis (27%) compared to patients on acalabrutinib (10%, p < 0.01) or zanubrutinib (9%, p < 0.01). Median (interquartile range [IQR]) laboratory visits at 12 months were higher for ibrutinib (5, 0–12) than acalabrutinib (1, 0–8, p < 0.01) or zanubrutinib (0, 0–6, p < 0.01). Finally, overall survival (OS) was higher for patients on zanubrutinib than those on ibrutinib (p < 0.01) or acalabrutinib (p < 0.01). Conclusions: Patients prescribed acalabrutinib and zanubrutinib experienced fewer laboratory and hematology/oncology visits at 12 months than patients who received ibrutinib. Patients who received zanubrutinib experienced a survival advantage when compared to those treated with ibrutinib.
- Open Access
- 21 May 2026
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 75 (5) , 002169
Elevated urinary glycosaminoglycans in Staphylococcus aureus bacteraemia with endovascular source
The differentiation of endovascular sources of Staphylococcus aureus bacteraemia from non-endovascular infection carries significant prognostic information that can be used to therapeutically stratify patients. The endovascular glycocalyx is a protective barrier composed of glycosaminoglycans (GAGs) that can be degraded and excreted in the urine from endothelial injury occurring in endovascular infections, but not in non-endovascular infections. To determine whether patients who had S. aureus endovascular infections, including endocarditis, had increased urinary glycocalyx shedding suggestive of endothelial damage, urine samples from 55 patients with bacteraemia caused by S. aureus were assessed for GAG content. Patients with endovascular source bacteraemia were compared to those from non-vascular source bacteraemia (e.g. prosthetic joint infections, pyomyositis and cellulitis) for GAG content. As expected, patients with S. aureus bacteraemia stemming from endovascular foci of infection showed increased GAG content in the urine (24.11±4.9 g GAG/mol creatinine, n =22) compared to those with non-vascular infections (13.65±1.6 g GAG/mol creatinine, n =33, P =0.024). Further analysis of GAG composition in urine revealed differential presence of GAGs between these two groups. In the first pilot study of its kind, we found that the measurement of GAG in the urine of patients with S. aureus bacteraemia shows promise for clinical risk stratification to identify high-risk endovascular infections in order to guide clinical diagnostic and therapeutic decision-making. Larger studies will be needed to determine relevant quantitative cut-off values.
- 21 May 2026
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 75 (5) , 002169
Open AccessElevated urinary glycosaminoglycans in Staphylococcus aureus bacteraemia with endovascular source
The differentiation of endovascular sources of Staphylococcus aureus bacteraemia from non-endovascular infection carries significant prognostic information that can be used to therapeutically stratify patients. The endovascular glycocalyx is a protective barrier composed of glycosaminoglycans (GAGs) that can be degraded and excreted in the urine from endothelial injury occurring in endovascular infections, but not in non-endovascular infections. To determine whether patients who had S. aureus endovascular infections, including endocarditis, had increased urinary glycocalyx shedding suggestive of endothelial damage, urine samples from 55 patients with bacteraemia caused by S. aureus were assessed for GAG content. Patients with endovascular source bacteraemia were compared to those from non-vascular source bacteraemia (e.g. prosthetic joint infections, pyomyositis and cellulitis) for GAG content. As expected, patients with S. aureus bacteraemia stemming from endovascular foci of infection showed increased GAG content in the urine (24.11±4.9 g GAG/mol creatinine, n =22) compared to those with non-vascular infections (13.65±1.6 g GAG/mol creatinine, n =33, P =0.024). Further analysis of GAG composition in urine revealed differential presence of GAGs between these two groups. In the first pilot study of its kind, we found that the measurement of GAG in the urine of patients with S. aureus bacteraemia shows promise for clinical risk stratification to identify high-risk endovascular infections in order to guide clinical diagnostic and therapeutic decision-making. Larger studies will be needed to determine relevant quantitative cut-off values.
- Open Access
- 6 May 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (3)
Successful clearance of persistent Staphylococcus aureus pneumonia with high-dose continuous infusion cefazolin
Background: Deep-seated Staphylococcus aureus infections are difficult to treat and require appropriate antibiotic regimens for clinical success. Recent studies have shown that continuous infusion (CI) of β-lactam antibiotics is associated with reduced mortality, though optimal dosages remain to be determined. Here, we present a case in which high-dose cefazolin, at 10 g daily CI, was used to safely and successfully clear methicillin-susceptible S. aureus (MSSA) pneumonia. Case Summary: A 33-year-old male was admitted to the medical intensive care unit with suspected MSSA community-acquired pneumonia. Over the course of a 43-day hospital stay, the patient’s pneumonia relapsed twice following two 5- to 7-day courses of cefazolin 8 g daily CI. Clearance of the pneumonia was achieved after a 14-day course of cefazolin 10 g daily CI, and the patient was discharged. Conclusion: Here, we describe a patient with incomplete clearance of MSSA pneumonia despite two 5- to 7-day courses of cefazolin 8 g daily CI. Following a 14-day course of cefazolin 10 g daily CI, the patient’s fever and leukocytosis rapidly resolved without direct evidence of drug-related toxicity. This case report provides evidence for the safe and effective use of high-dose cefazolin CI in the clearance of persistent MSSA pneumonia.
- 6 May 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (3)
Open AccessSuccessful clearance of persistent Staphylococcus aureus pneumonia with high-dose continuous infusion cefazolin
Background: Deep-seated Staphylococcus aureus infections are difficult to treat and require appropriate antibiotic regimens for clinical success. Recent studies have shown that continuous infusion (CI) of β-lactam antibiotics is associated with reduced mortality, though optimal dosages remain to be determined. Here, we present a case in which high-dose cefazolin, at 10 g daily CI, was used to safely and successfully clear methicillin-susceptible S. aureus (MSSA) pneumonia. Case Summary: A 33-year-old male was admitted to the medical intensive care unit with suspected MSSA community-acquired pneumonia. Over the course of a 43-day hospital stay, the patient’s pneumonia relapsed twice following two 5- to 7-day courses of cefazolin 8 g daily CI. Clearance of the pneumonia was achieved after a 14-day course of cefazolin 10 g daily CI, and the patient was discharged. Conclusion: Here, we describe a patient with incomplete clearance of MSSA pneumonia despite two 5- to 7-day courses of cefazolin 8 g daily CI. Following a 14-day course of cefazolin 10 g daily CI, the patient’s fever and leukocytosis rapidly resolved without direct evidence of drug-related toxicity. This case report provides evidence for the safe and effective use of high-dose cefazolin CI in the clearance of persistent MSSA pneumonia.
- Open Access
- 13 February 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (2) , 185
Diverse Role of blaCTX-M and Porins in Mediating Ertapenem Resistance among Carbapenem-Resistant Enterobacterales
Among carbapenem-resistant Enterobacterales (CRE) are diverse mechanisms, including those that are resistant to meropenem but susceptible to ertapenem, adding further complexity to the clinical landscape. This study investigates the emergence of ertapenem-resistant, meropenem-susceptible (ErMs) Escherichia coli and Klebsiella pneumoniae CRE across five hospitals in San Antonio, Texas, USA, from 2012 to 2018. The majority of the CRE isolates were non-carbapenemase producers (NCP; 54%; 41/76); 56% of all NCP isolates had an ErMs phenotype. Among ErMs strains, E. coli comprised the majority (72%). ErMs strains carrying blaCTX-M had, on average, 9-fold higher copies of blaCTX-M than CP-ErMs strains as well as approximately 4-fold more copies than blaCTX-M-positive but ertapenem- and meropenem-susceptible (EsMs) strains (3.7 vs. 0.9, p < 0.001). Notably, carbapenem hydrolysis was observed to be mediated by strains harboring blaCTX-M with and without a carbapenemase(s). ErMs also carried more mobile genetic elements, particularly IS26 composite transposons, than EsMs (37 vs. 0.2, p < 0.0001). MGE- ISVsa5 was uniquely more abundant in ErMs than either EsMs or ErMr strains, with over 30 more average ISVsa5 counts than both phenotype groups (p < 0.0001). Immunoblot analysis demonstrated the absence of OmpC expression in NCP-ErMs E. coli, with 92% of strains lacking full contig coverage of ompC. Overall, our findings characterize both collaborative and independent efforts between blaCTX-M and OmpC in ErMs strains, indicating the need to reappraise the term “non-carbapenemase (NCP)”, particularly for strains highly expressing blaCTX-M. To improve outcomes for CRE-infected patients, future efforts should focus on mechanisms underlying the emerging ErMs subphenotype of CRE strains to develop technologies for its rapid detection and provide targeted therapeutic strategies.
- 13 February 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (2) , 185
Open AccessDiverse Role of blaCTX-M and Porins in Mediating Ertapenem Resistance among Carbapenem-Resistant Enterobacterales
Among carbapenem-resistant Enterobacterales (CRE) are diverse mechanisms, including those that are resistant to meropenem but susceptible to ertapenem, adding further complexity to the clinical landscape. This study investigates the emergence of ertapenem-resistant, meropenem-susceptible (ErMs) Escherichia coli and Klebsiella pneumoniae CRE across five hospitals in San Antonio, Texas, USA, from 2012 to 2018. The majority of the CRE isolates were non-carbapenemase producers (NCP; 54%; 41/76); 56% of all NCP isolates had an ErMs phenotype. Among ErMs strains, E. coli comprised the majority (72%). ErMs strains carrying blaCTX-M had, on average, 9-fold higher copies of blaCTX-M than CP-ErMs strains as well as approximately 4-fold more copies than blaCTX-M-positive but ertapenem- and meropenem-susceptible (EsMs) strains (3.7 vs. 0.9, p < 0.001). Notably, carbapenem hydrolysis was observed to be mediated by strains harboring blaCTX-M with and without a carbapenemase(s). ErMs also carried more mobile genetic elements, particularly IS26 composite transposons, than EsMs (37 vs. 0.2, p < 0.0001). MGE- ISVsa5 was uniquely more abundant in ErMs than either EsMs or ErMr strains, with over 30 more average ISVsa5 counts than both phenotype groups (p < 0.0001). Immunoblot analysis demonstrated the absence of OmpC expression in NCP-ErMs E. coli, with 92% of strains lacking full contig coverage of ompC. Overall, our findings characterize both collaborative and independent efforts between blaCTX-M and OmpC in ErMs strains, indicating the need to reappraise the term “non-carbapenemase (NCP)”, particularly for strains highly expressing blaCTX-M. To improve outcomes for CRE-infected patients, future efforts should focus on mechanisms underlying the emerging ErMs subphenotype of CRE strains to develop technologies for its rapid detection and provide targeted therapeutic strategies.
- Open Access
- 3 January 2024
- Published by MDPI AG in Preprints.org
Diverse Role of blaCTX-M and Porins in Mediating Ertapenem Resistance Among Carbapenem Resistant Enterobacterales
This study investigates the emergence of ertapenem-resistant, meropenem-susceptible (ErMs) among non-carbapenemase producing (NCP) and carbapenemase producing (CP) Escherichia coli and Klebsiella pneumoniae. As mutations for ertapenem resistance establish the genetic background for non-carbapenemase meropenem resistance, there is a great need for antibiotic stewards and researchers to understand the determinants of a strain’s propensity to become resistant. Whole genome sequencing was conducted on clinical carbapenem-resistant E. coli (CREC) and K. pneumoniae (CRKP) across 5 hospitals in San Antonio, U.S. from 2012-2018. The majority of carbapenem resistant Enterobacterales (CRE) were NCP (54%; 41/76). The blaCTX-M was found to be most prevalent among NCP isolates (p = 0.02). LC-MS/MS analysis of carbapenem hydrolysis revealed that blaCTX-M-mediated carbapenem hydrolysis, indicating the need to reappraise the term, “non-carbapenemase (NCP)” for quantitatively uncharacterized CRE strains harboring blaCTX-M. Antimicrobial susceptibility results showed that 56% of all NCPE isolates had an ErMs phenotype (NCPE vs. CPE, p < 0.001), with E. coli driving the phenotype (E. coli vs. K. pneumoniae, p < 0.001). ErMs strains carrying blaCTX-M, had approximately 4-fold more copies of blaCTX-M than ceftriaxone-resistant but ertapenem and meropenem susceptible (EsMs) isolates (3.7 v. 0.9, p < 0.001). ErMs also carried more mobile genetic elements (MGEs), particularly IS26 composite transposons, than EsMs (37 vs. 0.2, p < 0.0001). Immunoblot analysis demonstrated the absence of OmpC expression in NCP-ErMs E. coli, with 92% of strains lacking full contig coverage of ompC. Overall, this work provides evidence of a collaborative effort between blaCTX-M and OmpC in NCP strains that confer resistance to ertapenem but not meropenem. To thwart potential mismanagement of CRE infected patients, future efforts should focus on understanding the mechanism(s) underlying OmpC loss, developing rapid methods to detect blaCTX-M copy number variants, and targeted antimicrobials for NCPE and ErMs strains.
- 3 January 2024
- Published by MDPI AG in Preprints.org
Open AccessDiverse Role of blaCTX-M and Porins in Mediating Ertapenem Resistance Among Carbapenem Resistant Enterobacterales
This study investigates the emergence of ertapenem-resistant, meropenem-susceptible (ErMs) among non-carbapenemase producing (NCP) and carbapenemase producing (CP) Escherichia coli and Klebsiella pneumoniae. As mutations for ertapenem resistance establish the genetic background for non-carbapenemase meropenem resistance, there is a great need for antibiotic stewards and researchers to understand the determinants of a strain’s propensity to become resistant. Whole genome sequencing was conducted on clinical carbapenem-resistant E. coli (CREC) and K. pneumoniae (CRKP) across 5 hospitals in San Antonio, U.S. from 2012-2018. The majority of carbapenem resistant Enterobacterales (CRE) were NCP (54%; 41/76). The blaCTX-M was found to be most prevalent among NCP isolates (p = 0.02). LC-MS/MS analysis of carbapenem hydrolysis revealed that blaCTX-M-mediated carbapenem hydrolysis, indicating the need to reappraise the term, “non-carbapenemase (NCP)” for quantitatively uncharacterized CRE strains harboring blaCTX-M. Antimicrobial susceptibility results showed that 56% of all NCPE isolates had an ErMs phenotype (NCPE vs. CPE, p < 0.001), with E. coli driving the phenotype (E. coli vs. K. pneumoniae, p < 0.001). ErMs strains carrying blaCTX-M, had approximately 4-fold more copies of blaCTX-M than ceftriaxone-resistant but ertapenem and meropenem susceptible (EsMs) isolates (3.7 v. 0.9, p < 0.001). ErMs also carried more mobile genetic elements (MGEs), particularly IS26 composite transposons, than EsMs (37 vs. 0.2, p < 0.0001). Immunoblot analysis demonstrated the absence of OmpC expression in NCP-ErMs E. coli, with 92% of strains lacking full contig coverage of ompC. Overall, this work provides evidence of a collaborative effort between blaCTX-M and OmpC in NCP strains that confer resistance to ertapenem but not meropenem. To thwart potential mismanagement of CRE infected patients, future efforts should focus on understanding the mechanism(s) underlying OmpC loss, developing rapid methods to detect blaCTX-M copy number variants, and targeted antimicrobials for NCPE and ErMs strains.
- 15 February 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (2) , e0216621
Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?
Cefazolin and ertapenem have been shown to be an effective salvage regimen for refractory methicillin-susceptible Staphylococcus aureus bacteremia. Our findings suggest cefazolin plus ertapenem in vitro stimulates interleukin-1β release from peripheral blood monocytes both with and without S. aureus presence.
- 15 February 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (2) , e0216621
Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?
Cefazolin and ertapenem have been shown to be an effective salvage regimen for refractory methicillin-susceptible Staphylococcus aureus bacteremia. Our findings suggest cefazolin plus ertapenem in vitro stimulates interleukin-1β release from peripheral blood monocytes both with and without S. aureus presence.